Laboratorios Rovi : Rules out entry of PE investors in its CDMO business
>Management wants to continue its CDMO business on its own - The company has just unveiled, via a regulatory filing, that they discard the option of selling/sharing its CDMO business with a third-party investor after assessing the non-binding offers received that, apparently, were pointing to a >€ 3bn valuation. Earlier this year, the company has been evaluating strategic options for its assets including a potential sale of a stake in its third-party contract develop...Laboratorios Farmaceuticos Rovi is engaged in the sale of its own pharmaceutical products and the distribution of other products for which it holds licenses granted by other laboratories for specific periods, in accordance with the terms and conditions contained in the agreements entered into with said laboratories.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.